CADD522, Acta Societatis Bonecae Oncologiae, University of East Anglia's School Medical Norwich

Novum pharmacum pro prima os cancri in pueris

March 2023: The scientists who developed a new drug that may be effective against all major types of primary bone cancer in children have called it "the most significant drug discovery in the field in nearly half a century." T..

Isque princeps onus, immunotherapy, KEYTRUDA, Pembrolizumab, H VUL

Quis probatus est in usu Pembrolizumab ad cancer tumor et altum onus mutational

Iulii 2021: In US Cibus et Medication Administration (FDA) indicia pembrolizumab (Keytruda), immunotherapyium medicamentum dilatavit, ut quodvis cancer cum magno mutationis onere comprehenderet (TMB-H). Nova auctoritas est f.

Ne forte cancer de uva exprimitur non manducans

Aliqua inquisitio ostendit uvas edendi ne cancer. Malignitas pulmonis genus tumoris in planeta est maximum, et 80% mortium fumigantium sociatur. Non obstante tabaci potestate, chemoprevention techniq cogens.